Drugs / interferon-α
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06130579 | Jan 2024 → Dec 2025 overdue | myelodysplastic syndrome, myeloid leukemia | Peking University People's Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interferon-α | “The dose of interferon-α was 3 million units/time, subcutaneously injected twice a week.” NCT06130579 ↗ |
| Known as | IFN-Α | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06130579 ↗ |
| Route | Subcutaneous | “subcutaneously injected” NCT06130579 ↗ |